New drug duo targets deadly brain TB in early trial
NCT ID NCT07350174
First seen Jan 28, 2026 · Last updated May 08, 2026 · Updated 15 times
Summary
This study tests a new two-drug combination (Alpibectir and Ethionamide) added to standard treatment for tuberculosis meningitis, a serious brain infection. About 64 adults with newly diagnosed TB meningitis will receive either the new combo or standard care. The main goal is to measure how much drug reaches the blood and spinal fluid, and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS MENINGITIS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.